呼吸道合胞病毒表位重組蛋白的初步研究
本文關(guān)鍵詞: 呼吸道合胞病毒 表位預(yù)測 F蛋白 G蛋白 中和表位 出處:《西北農(nóng)林科技大學(xué)》2009年碩士論文 論文類型:學(xué)位論文
【摘要】: 呼吸道合胞病毒( Respiratory syncytial virus,RSV)是引起嬰幼兒和易感成人呼吸道感染最主要的病毒性病原。它除了引起上呼吸道感染外,還是引起毛細(xì)支氣管肺炎等下呼吸道感染的重要原因。自然感染率極高,對(duì)嬰幼兒、老年人及免疫抑制患者能引起嚴(yán)重的下呼吸道炎癥反應(yīng)。世界衛(wèi)生組織(WHO)十分重視該疫苗的開發(fā),呼吁開發(fā)安全有效的RSV疫苗。但由于多種限制因素,例如:RSV A、B兩亞型交錯(cuò)出現(xiàn)、選擇合適的載體蛋白較困難等問題,迄今尚無成功的疫苗問世。 為尋求可以用于RSV疫苗研制的表位,在病毒吸附蛋白(G蛋白)和融合蛋白(F蛋白)中尋找合適的中和表位,以Balb/c小鼠為動(dòng)物模型,通過動(dòng)物試驗(yàn)檢測中和表位的效果。 通過對(duì)吸附蛋白和融合蛋白的生物信息學(xué)預(yù)測和文獻(xiàn)調(diào)研查找,從G蛋白中篩選出五個(gè)比較集中的表位,其位于G142-204中,最終選擇了G142-204(命名為G)這段區(qū)間作為研究對(duì)象。從F蛋白篩選出兩個(gè)表位F205-223和F255-278,使用剛性linker(GPG)來連接,最終選擇F205-223-GPG-F255-278(命名為F)作為研究對(duì)象。采用重疊PCR技術(shù),構(gòu)建了編碼G142-204和Balb/c小鼠血清白蛋白結(jié)構(gòu)域Ⅰ的融合基因(命名為G-M)、F205-223-GPG-F255-278和Balb/c小鼠血清白蛋白結(jié)構(gòu)域Ⅰ的融合基因(命名為F-M)。將融合基因成功構(gòu)建在原核表達(dá)載體pET28a(+)上,并在大腸埃希菌BL21(DE3)表達(dá)。經(jīng)檢測目的蛋白是以包涵體形式表達(dá),采用尿素變性,親和層析法純化,獲得高純度的融合蛋白,純度達(dá)到90%。融合蛋白免疫9周齡的雌性Balb/c小鼠,采集小鼠血液,通過ELISA法檢測血清中特異性抗體的抗體亞型,F-M蛋白免疫組IgG1/IgG2a比值為1.47,相比之下,較G-M更趨向于Th1/Th2之間的平衡。免疫融合蛋白后Balb/c小鼠肺部及血清中均能產(chǎn)生抗RSV抗體。免疫小鼠RSV攻毒試驗(yàn),F-M免疫組與G-M免疫組都能夠起到保護(hù)肺部、降低肺部病毒滴度的作用。本試驗(yàn)制備的融合蛋白具有一定的病毒中和能力,經(jīng)過進(jìn)一步的試驗(yàn)印證后,有望開發(fā)出一種更加安全有效的RSV疫苗。
[Abstract]:Respiratory syncytial virus (Respiratory syncytial, virus, RSV) is caused by susceptible infants and adult respiratory tract infection is the main pathogenic viruses. In addition it cause upper respiratory tract infection, or cause capillary bronchial pneumonia and other lower respiratory tract infections. The natural infection rate is very high, for infants and young children, the elderly and immunosuppressed patients the lower respiratory tract caused by severe inflammatory reaction. The WHO (WHO) attaches great importance to the development of the vaccine, called for the development of safe and effective RSV vaccine. But due to the limitation of various factors, such as: RSV A, B two subtypes staggered, the appropriate carrier protein is difficult, so far there is no successful advent of vaccines.
In order to find epitope suitable for the development of RSV vaccine, find suitable neutralizing epitope in virus adsorbed protein (G protein) and fusion protein (F protein), and Balb/c mice as animal model, and detect the effect of neutralization epitope by animal test.
The adsorption of protein and fusion protein bioinformatics prediction and literature search, from the G protein were screened five more concentrated epitopes, which is located in G142-204, finally chose G142-204 (named G) of this section as the research object. From the F protein and selected two epitopes of F205-223 and F255-278 linker (GPG), the use of rigid connection, the final choice of F205-223-GPG-F255-278 (named F) as the research object. By using the overlapping PCR technology, constructed the recombinant encoding G142-204 and Balb/c mice serum albumin domain I gene (named G-M), serum albumin fusion domain I F205-223-GPG-F255-278 and Balb/c mouse gene (named F-M). The fusion gene was successfully constructed in prokaryotic expression vector pET28a (+), and in Escherichia coli BL21 (DE3). The expression of the target proteins were expressed in the form of inclusion bodies, using urea denaturation, affinity Chromatography, high purity fusion protein was obtained, the purity of 90%. protein in 9 week old female Balb/c mice were collected by blood, specific antibodies in serum were measured by ELISA antibody subtype, F-M protein IgG1/IgG2a ratio was 1.47, compared with G-M tend to Th1/Th2 balance. The immune fusion protein in lungs and serum of Balb/c mice can produce anti RSV antibody in immunized mice. RSV challenge test, F-M group and G-M group are immune immunity can protect the lungs and reduce the virus titer of lung function. The experimental preparation of fusion protein had the virus neutralizing ability, after further tests confirmed later, is expected to develop a more safe and effective RSV vaccine.
【學(xué)位授予單位】:西北農(nóng)林科技大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2009
【分類號(hào)】:R392
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 楊曉麗;武靜;;布地奈德吸入預(yù)防呼吸道合胞病毒感染后哮喘的療效觀察[J];實(shí)用心腦肺血管病雜志;2011年08期
2 劉恩梅;彭才靜;;呼吸道合胞病毒感染防治進(jìn)展[J];臨床兒科雜志;2011年08期
3 董林;王艷萍;苗立中;沈志強(qiáng);;表位疫苗設(shè)計(jì)、優(yōu)化策略及在動(dòng)物疫苗研究中的應(yīng)用[J];畜牧與獸醫(yī);2011年06期
4 朱秋麗;張濤;丁云芳;張學(xué)蘭;趙根明;;呼吸道合胞病毒感染兒童住院費(fèi)用影響因素的回歸樹分析[J];復(fù)旦學(xué)報(bào)(醫(yī)學(xué)版);2011年04期
5 葉新民;鐘南山;劉春麗;陳如沖;趙謹(jǐn);;呼吸道合胞病毒感染對(duì)豚鼠咳嗽相關(guān)氣道功能及其神經(jīng)遞質(zhì)的影響[J];中華哮喘雜志(電子版);2011年03期
6 周淑新;梁劍虹;;兒童呼吸道合胞病毒感染[J];中國全科醫(yī)學(xué);2011年19期
7 鄭小莉;張藝;謝曉東;羅波;劉佳佳;;鼠Mincle蛋白B細(xì)胞抗原表位預(yù)測及多克隆抗體制備[J];免疫學(xué)雜志;2011年08期
8 王藹紅;;喜炎平治療毛細(xì)支氣管炎的療效觀察[J];遼寧醫(yī)學(xué)雜志;2011年04期
9 劉麗娜;潘渠;朱軍民;叢延廣;劉紅美;李程;;2-型豬鏈球菌保護(hù)性抗原RfeA的B細(xì)胞表位預(yù)測[J];成都醫(yī)學(xué)院學(xué)報(bào);2011年02期
10 盧光全;李儒貴;白淑霞;;酚妥拉明聯(lián)合布地奈德佐治小兒毛細(xì)支氣管炎療效觀察[J];山西醫(yī)藥雜志(下半月刊);2011年07期
相關(guān)會(huì)議論文 前10條
1 姚翠梅;韓文愈;雷連成;孫長江;劉珊珊;;CD4~+T細(xì)胞表位預(yù)測及其應(yīng)用[A];中國畜牧獸醫(yī)學(xué)會(huì)生物制品學(xué)分會(huì)中國微生物學(xué)會(huì)獸醫(yī)微生物學(xué)專業(yè)委員會(huì)2010年學(xué)術(shù)年會(huì)(第三屆中國獸藥大會(huì)學(xué)術(shù)論壇)論文集[C];2010年
2 李雯;沈華浩;;呼吸道合胞病毒感染對(duì)小鼠基質(zhì)金屬蛋白酶的影響[A];2006年浙江省內(nèi)科學(xué)學(xué)術(shù)年會(huì)、2006年浙江省老年醫(yī)學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2006年
3 姜淑娟;陳方方;賈婷;楊艷娜;;呼吸道合胞病毒感染與支氣管哮喘激素抵抗機(jī)制的實(shí)驗(yàn)研究[A];中華醫(yī)學(xué)會(huì)第七次全國呼吸病學(xué)術(shù)會(huì)議暨學(xué)習(xí)班論文匯編[C];2006年
4 孫聰;楊閩楠;賽度;張泉鵬;黃志強(qiáng);丁壯;;鵝源副黏病毒NA-1株F蛋白結(jié)構(gòu)與B細(xì)胞抗原表位預(yù)測[A];中國畜牧獸醫(yī)學(xué)會(huì)獸醫(yī)公共衛(wèi)生學(xué)分會(huì)第三次學(xué)術(shù)研討會(huì)論文集[C];2012年
5 王開功;陳軍義;周碧君;文明;程振濤;劉飛;;PRRSV-GP5基因的克隆及其蛋白結(jié)構(gòu)和B細(xì)胞表位預(yù)測[A];中國畜牧獸醫(yī)學(xué)會(huì)2010年學(xué)術(shù)年會(huì)——第二屆中國獸醫(yī)臨床大會(huì)論文集(下冊(cè))[C];2010年
6 劉崇海;楊錫強(qiáng);;樹,
本文編號(hào):1476046
本文鏈接:http://sikaile.net/yixuelunwen/shiyanyixue/1476046.html